Back to top
more

Kite Pharma, Inc. (KITE)

(Delayed Data from NSDQ)

$179.79 USD

179.79
3,761,989

-0.02 (-0.01%)

Updated Oct 2, 2017 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Keryx Releases Auryxia Data for Iron Deficiency Anemia

Keryx Biopharmaceuticals, Inc. (KERX) recently announced the publication of results from a phase III in the online issue of the Journal of the American Society of Nephrology (JASN).

    Novartis to Conduct Trial on Obese, Type II Diabetes Patients

    In a recent announcement, MorphoSys AG mentioned that its partner Swiss major Novartis AG (NVS) will conduct a phase II clinical trial on pipeline candidate bimagrumab in obese patients with type II diabetes.

      TESARO Varubi IV Gets Complete Response Letter in the U.S.

      TESARO (TSRO) announced that it has received a Complete Response Letter from the FDA regarding its NDA for Varubi IV.

        Pluristem (PSTI) Intermittent Claudication Study Enrolled

        Pluristem Therapeutics (PSTI) has completed patient enrollment in a phase II study on PLX-PAD cells for the treatment of intermittent claudication.

          TherapeuticsMD's Rejoice Study Data Published in Journal

          TherapeuticsMD, Inc. (TXMD) announced the publication of two manuscripts detailing with the results of the company's pivotal phase III study (Rejoice) in Menopause: The Journal of The North American Menopause Society.

            Lilly, Merck Expand Tie-Up to Study Lartruvo-Keytruda Combo

            Eli Lilly and Company (LLY) and Merck & Co., Inc. (MRK) expanded their existing immuno-oncology partnership to include a new study that will evaluate Lilly???s Lartruvo in combination with Merck???s Keytruda in patients with STS.

              Gilead (GILD) HBV Drug Vemlidy Receives European Approval

              Gilead Sciences (GILD) gained EU approval for Vemlidy for the treatment of chronic HBV infection.

                Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU

                Alexion (ALXN) has filed regulatory applications in both the U.S. and EU for Soliris for the treatment of patients with refractory generalized myasthenia gravis.

                  Amgen: Phase III Data on Hyperparathyroidism Drug Published

                  Amgen Inc. (AMGN) announced that data from three phase III studies on its pipeline candidate, Parsabiv (etelcalcetide), were published in the Journal of the American Medical Association (JAMA).

                    Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases

                    Sanofi (SNY) announced an agreement with ImmuNext, Inc. for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis.

                      Kite Pharma Inks Deals for CAR T Cell Drug in Japan, China

                      Kite Pharma (KITE) announced that it has entered into a strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (KTE-C19) in Japan.

                        Emergent Down on '17 View, Posts Preliminary '16 Results

                        Emergent announced better-than-expected preliminary 2016 results. However, the outlook for 2017 fell short of estimates.

                          Arpita Dutt headshot

                          4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal

                          Takeda to Buy ARIAD, More M&As to Follow in Biotech Sector?

                            Incyte/Merck to Start More Epacadostat-Keytruda Studies

                            Incyte (INCY) and Merck (MRK) announced that they have decided to initiate additional pivotal studies on epacadostat, in combination with Merck's Keytruda.

                              AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder

                              AMAG (AMAG) announced that it has entered into an agreement with Palatin (PTN) for the exclusive U.S. rights to develop and commercialize Rekynda.

                                AbbVie's HCV Combo Favorable in Japanese Phase III Study

                                AbbVie Inc. (ABBV) announced positive top-line data from a phase III study on its pan-genotypic ribavirin (RBV)-free regimen of glecaprevir/pibrentasvir (G/P) in Japanese patients.

                                  ARIAD Pharma Stock Gains on Acquisition Deal with Takeda

                                  ARIAD Pharmaceuticals, Inc.'s (ARIA) shares surged 72.8% after the company announced a definitive agreement to be acquired by Japan-based Takeda Pharmaceutical Company Limited (TKPYY) for approximately $5.2 billion.

                                    Kite Pharma (KITE) to Move Cancer Candidate into Phase I

                                    Kite Pharma, Inc. (KITE) announced that it has filed a Investigational New Drug (IND) application with the FDA to initiate phase I studies on KITE-718, a TCR candidate targeting MAGE in a solid tumor.

                                      Kite Pharma Enters into Partnership with Vitruvian Networks

                                      Kite Pharma (KITE) entered into a strategic partnership with Vitruvian Networks to create a software solution to support commercial availability of T-cell therapies.

                                        Kite Pharma Begins Filing for KTE-C19, Presents Data at ASH

                                        Kite Pharma, Inc. (KITE) announced it has initiated a rolling submission of the Biologic License Application (BLA) for its lead pipeline candidate, KTE-C19, to the FDA.